Shaker Investments LLC OH Boosts Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Shaker Investments LLC OH boosted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,833 shares of the medical instruments supplier’s stock after buying an additional 175 shares during the quarter. Shaker Investments LLC OH owned 0.06% of LeMaitre Vascular worth $1,138,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Mesirow Institutional Investment Management Inc. bought a new stake in shares of LeMaitre Vascular during the fourth quarter worth $8,837,000. Congress Asset Management Co. MA lifted its position in shares of LeMaitre Vascular by 17.0% during the fourth quarter. Congress Asset Management Co. MA now owns 594,672 shares of the medical instruments supplier’s stock worth $33,754,000 after purchasing an additional 86,293 shares during the last quarter. Summit Creek Advisors LLC lifted its position in shares of LeMaitre Vascular by 37.8% during the fourth quarter. Summit Creek Advisors LLC now owns 228,501 shares of the medical instruments supplier’s stock worth $12,970,000 after purchasing an additional 62,737 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of LeMaitre Vascular by 554.7% during the first quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after purchasing an additional 47,218 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of LeMaitre Vascular by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock worth $87,914,000 after purchasing an additional 38,303 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Barrington Research lifted their target price on LeMaitre Vascular from $79.00 to $92.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. StockNews.com upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Monday, August 12th. Lake Street Capital assumed coverage on LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective for the company. Roth Capital upgraded LeMaitre Vascular to a “strong-buy” rating in a report on Friday, May 31st. Finally, JMP Securities lifted their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, LeMaitre Vascular has a consensus rating of “Buy” and a consensus price target of $90.33.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock traded down $0.91 during trading hours on Monday, reaching $90.76. The stock had a trading volume of 111,079 shares, compared to its average volume of 127,469. The company has a market cap of $2.04 billion, a price-to-earnings ratio of 60.11, a PEG ratio of 2.63 and a beta of 0.89. The business’s 50 day moving average price is $84.45 and its 200-day moving average price is $74.81. LeMaitre Vascular, Inc. has a 52 week low of $44.27 and a 52 week high of $92.90.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The business had revenue of $55.85 million during the quarter, compared to the consensus estimate of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.63%. The firm’s revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.37 earnings per share. On average, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 29th. Investors of record on Thursday, August 15th will be given a $0.16 dividend. The ex-dividend date is Thursday, August 15th. This represents a $0.64 dividend on an annualized basis and a yield of 0.71%. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 12,976 shares of the company’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $86.07, for a total value of $1,116,844.32. Following the sale, the chief executive officer now owns 1,985,358 shares in the company, valued at approximately $170,879,763.06. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO George W. Lemaitre sold 12,976 shares of the stock in a transaction on Friday, July 12th. The stock was sold at an average price of $86.07, for a total value of $1,116,844.32. Following the completion of the transaction, the chief executive officer now directly owns 1,985,358 shares of the company’s stock, valued at approximately $170,879,763.06. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction on Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the completion of the transaction, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The disclosure for this sale can be found here. Insiders have sold a total of 43,251 shares of company stock worth $3,714,994 over the last quarter. Insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.